(Q42926639)

English

Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients

scientific article published on 24 August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

Elisabetta Abruzzese

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Pier Luigi Zinzani

1

object named as

Pier Luigi Zinzani

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Gerardo Musuraca

object named as

Gerardo Musuraca

4

0 references

Maria Cantonetti

object named as

Maria Cantonetti

7

0 references

Michele Baccarani

9

object named as

Michele Baccarani

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Stefano A Pileri

10

object named as

Stefano A Pileri

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Amalia De Renzo

6

object named as

Amalia De Renzo

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Vittorio Stefoni

3

object named as

Vittorio Stefoni

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

author name string

Alessandro Broccoli

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Francesco Bacci

8

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

language of work or name

0 references

publication date

24 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

5667-5675

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Stromal gene signatures in large-B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25307

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25307

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42926639&oldid=1973910171"